Effect of primary tumor side on survival outcomes in metastatic colorectal cancer patients after hepatic arterial infusion chemotherapy

Table 1 Patient characteristics

Variable	Left side (n = 135)	Right side (n = 33)	P-value
Age, mean (range), years	60.5 (27-85)	63.8 (37-83)	0.392
Men, n (%)	95 (70.4)	20 (60.6)	0.279
Previous system treatment, n (%)			0.455
Only first line	89 (65.9)	24 (72.7)
Second line or more	46 (34.1)	9 (27.3)
Extrahepatic metastasis, n (%)	73 (54.1)	21 (63.6)	0.321
Primary tumor resected, n (%)			0.173
No surgery	22 (16.2)	10 (30.3)
Palliative surgery	49 (36.3)	11 (33.3)
Radical surgery	64 (47.4)	12 (36.4)
Synchronous metastases, n (%)	103 (76.3)	26 (78.8)	0.761
Gene status, n (%)			0.127
KRAS mutation	17 (35.6)	8 (24.2)
KRAS wild type	48 (12.6)	7 (21.2)
Unknown	70 (51.9)	18 (54.5)
Targeted therapy, n (%)
Bevacizumab treated	27 (14.8)	2 (6.1)	0.21
Cetuximab treated	13 (9.6)	3 (9.1)
Other local treatment, n (%)	31 (23)	4 (12.1)	0.169
Repeated times of HAIC, n (%)			0.554
2	29 (21.5)	10 (30.3)
3-4	43 (21.9)	10 (30.3)
> 6	63 (46.7)	13 (39.4)

HAIC: Hepatic arterial infusion chemotherapy.